GHRP-2
Tissue & recoveryAlso known as Pralmorelin, KP-102
Evidence tier
Substantial published literature
256 publications over 33 years · trials not yet curated
- Researched since
- 1993
- Publications
- 256
- Mean purity
- —
- Vendors listing
- 2
No indexed vendor publishes certificate records for GHRP-2 that this index could read yet, so no purity comparison is possible.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1993 — 33 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
256 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
2 of 2 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is GHRP-2?
A growth-hormone-releasing peptide (also known as pralmorelin) studied for stimulating growth hormone secretion.
Studied in published research for growth-hormone release and recovery.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in human growth-hormone-secretion research; approved as a diagnostic in some countries. PepIndex does not evaluate clinical significance and does not describe administration.
- Ipamorelin, the first selective growth hormone secretagogue — European journal of endocrinology (1998)
Peer-reviewed article indexed in PubMed, published in European journal of endocrinology (1998).
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN — Drugs in R&D (2004)
Peer-reviewed article indexed in PubMed, published in Drugs in R&D (2004).
- Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry — Rapid communications in mass spectrometry : RCM (2010)
Peer-reviewed article indexed in PubMed, published in Rapid communications in mass spectrometry : RCM (2010).
- The Safety and Efficacy of Growth Hormone Secretagogues — Sexual medicine reviews (2018)
Peer-reviewed article indexed in PubMed, published in Sexual medicine reviews (2018).
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males — Translational andrology and urology (2020)
Peer-reviewed article indexed in PubMed, published in Translational andrology and urology (2020).
- Growth hormone-releasing peptides — European journal of endocrinology (1997)
Peer-reviewed article indexed in PubMed, published in European journal of endocrinology (1997).
- Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells — Endocrine (1998)
Peer-reviewed article indexed in PubMed, published in Endocrine (1998).
- GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans — Journal of pediatric endocrinology & metabolism : JPEM (1996)
Peer-reviewed article indexed in PubMed, published in Journal of pediatric endocrinology & metabolism : JPEM (1996).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| GenX Peptides | 75.168% | $4.00 (57%) | 0 | — | — | |
| Evo Labs Research | 67.189% | $10.00 (143%) | 0 | — | — |
Certificate records
No certificate records are indexed. Either none are published, or those published could not be read without an account.